NO20005889D0 - Benzimidazolanaloger som ned-regulatorer av IgE - Google Patents

Benzimidazolanaloger som ned-regulatorer av IgE

Info

Publication number
NO20005889D0
NO20005889D0 NO20005889A NO20005889A NO20005889D0 NO 20005889 D0 NO20005889 D0 NO 20005889D0 NO 20005889 A NO20005889 A NO 20005889A NO 20005889 A NO20005889 A NO 20005889A NO 20005889 D0 NO20005889 D0 NO 20005889D0
Authority
NO
Norway
Prior art keywords
ige
regulators
benzimidazole analogs
benzimidazole
analogs
Prior art date
Application number
NO20005889A
Other languages
English (en)
Other versions
NO20005889L (no
Inventor
Jagadish Sircar
Mark L Richards
Michael G Campbell
Michael W Major
Original Assignee
Avanir Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22198947&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20005889(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Avanir Pharmaceuticals filed Critical Avanir Pharmaceuticals
Publication of NO20005889D0 publication Critical patent/NO20005889D0/no
Publication of NO20005889L publication Critical patent/NO20005889L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Amplifiers (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
NO20005889A 1998-05-22 2000-11-21 Benzimidazolderivater som ned-regulatorer av IgE NO20005889L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8649498P 1998-05-22 1998-05-22
PCT/US1999/011490 WO1999061020A1 (en) 1998-05-22 1999-05-21 BENZIMIDAZOLE ANALOGS AS DOWN-REGULATORS OF IgE

Publications (2)

Publication Number Publication Date
NO20005889D0 true NO20005889D0 (no) 2000-11-21
NO20005889L NO20005889L (no) 2001-01-22

Family

ID=22198947

Family Applications (3)

Application Number Title Priority Date Filing Date
NO20005888A NO20005888L (no) 1998-05-22 2000-11-21 Benzimidazolderivater som mudulatorer av IgE
NO20005887A NO20005887L (no) 1998-05-22 2000-11-21 Forbindelser med IgE-påvirkende egenskaper
NO20005889A NO20005889L (no) 1998-05-22 2000-11-21 Benzimidazolderivater som ned-regulatorer av IgE

Family Applications Before (2)

Application Number Title Priority Date Filing Date
NO20005888A NO20005888L (no) 1998-05-22 2000-11-21 Benzimidazolderivater som mudulatorer av IgE
NO20005887A NO20005887L (no) 1998-05-22 2000-11-21 Forbindelser med IgE-påvirkende egenskaper

Country Status (22)

Country Link
US (2) US6271390B1 (no)
EP (3) EP1079830A1 (no)
JP (3) JP2002516276A (no)
KR (1) KR100591652B1 (no)
CN (4) CN1311675A (no)
AT (1) ATE292465T1 (no)
AU (3) AU754562B2 (no)
BR (3) BR9910640A (no)
CA (3) CA2332999A1 (no)
CZ (2) CZ20004350A3 (no)
DE (1) DE69924607T2 (no)
ES (1) ES2241285T3 (no)
HU (3) HUP0102550A3 (no)
IL (3) IL139827A0 (no)
MX (3) MXPA00011467A (no)
NO (3) NO20005888L (no)
NZ (2) NZ508416A (no)
PL (3) PL345952A1 (no)
RU (2) RU2236221C2 (no)
UA (2) UA67775C2 (no)
WO (3) WO1999061019A1 (no)
ZA (3) ZA200007754B (no)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6911462B2 (en) * 1998-05-22 2005-06-28 Avanir Pharmaceuticals Benzimidazole compounds for regulating IgE
US6919366B2 (en) * 1998-05-22 2005-07-19 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of IgE
CZ20004350A3 (cs) * 1998-05-22 2002-02-13 Avanir Pharmaceuticals Benzimidazolové deriváty jako modulátory IgE
JP4748338B2 (ja) 1998-09-11 2011-08-17 味の素株式会社 ベンゼン誘導体及びその医薬用途
US6270746B1 (en) * 1999-02-17 2001-08-07 David H. Katz Assay for the identification of IgE antibody suppressors
CN1353605A (zh) * 1999-03-26 2002-06-12 欧洲凯尔特股份有限公司 芳基取代的吡唑、咪唑、噁唑、噻唑和吡咯及其应用
EP1193255A4 (en) * 1999-07-01 2002-08-07 Ajinomoto Kk HETEROCYCLIC COMPOUNDS AND THEIR APPLICATIONS IN MEDICINE
WO2001016091A1 (fr) 1999-09-01 2001-03-08 Ajinomoto Co.,Inc. Composes amides d'acide biscyclopropanocarboxylique et utilisation medicinale de ces composes
US6759425B2 (en) 1999-10-21 2004-07-06 Avanir Pharmaceuticals Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
US20070208087A1 (en) 2001-11-02 2007-09-06 Sanders Virginia J Compounds, compositions and methods for the treatment of inflammatory diseases
ATE369853T1 (de) * 2001-03-12 2007-09-15 Avanir Pharmaceuticals Benzimidazolderivate zur ige-modulierung und zellproliferationshemmung
US8354397B2 (en) * 2001-07-27 2013-01-15 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
EP1435947B1 (en) 2001-10-19 2007-08-15 Ortho-McNeil Pharmaceutical, Inc. 2-phenyl benzimidazoles and imidazo-¬4,5|-pyridines as cds1/chk2-inhibitors and adjuvants to chemotherapy or radiation therapy in the treatment of cancer
US20080081788A1 (en) * 2002-01-14 2008-04-03 Lipps Binie V Diagnosis and treatment for immunoglobulin E (IgE) implicated disorders
US20030157555A1 (en) * 2002-01-14 2003-08-21 Lipps Binie V. Diagnosis and treatment for immunoglobulin E ( IgE) implicated disorders
TW200304820A (en) * 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
ES2473581T3 (es) 2002-05-31 2014-07-07 Proteotech Inc. Compuestos, composiciones y métodos para el tratamiento de amiloidosis y sinucleinopat�as tales como la enfermedad de Alzheimer, la diabetes de tipo 2 y la enfermedad de Parkinson
EP1388535A1 (en) * 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylated arylcycloalkylamines and their use as pharmaceuticals
DK1534335T4 (en) 2002-08-14 2015-10-05 Macrogenics Inc FCGAMMARIIB-SPECIFIC ANTIBODIES AND PROCEDURES FOR USE THEREOF
TWI276631B (en) 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
AU2003270426A1 (en) 2002-09-12 2004-04-30 Avanir Pharmaceuticals PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION
WO2004041280A1 (en) * 2002-11-02 2004-05-21 Kyung-Lim Lee Composition for preventing secretion of immunoglobulin e-dependent histamine releasing factor
GB2397301A (en) * 2003-01-14 2004-07-21 Novo Pharmaceuticals Ltd De Substituted 1,3,5-triazine derivatives
CA2522562C (en) 2003-04-17 2013-09-03 Janssen Pharmaceutica N.V. 2-phenyl-benzimidazol and 2-phenyl-imidazo-`4,5!-pyridine derivatives as checkpoint kinase cds1 (chk2) inhibitors for the treatment of cancer
JP2007501618A (ja) * 2003-08-08 2007-02-01 アバニール・ファーマシューティカルズ タンパク質輸送の選択的薬理学的阻害、および関連した、ヒト疾患を治療する方法
TWI368507B (en) 2004-02-20 2012-07-21 Boehringer Ingelheim Int Viral polymerase inhibitors
SG137850A1 (en) * 2004-05-12 2007-12-28 Proteotech Inc Substituted n-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies
EP1824832B1 (en) 2004-06-30 2011-04-27 Janssen Pharmaceutica NV Aryl-substituted benzimidazole and imidazopyridine ethers as anti-cancer agents
WO2006040645A1 (en) * 2004-10-11 2006-04-20 Ranbaxy Laboratories Limited N-(3,5-dichloropyridin-4-yl)-2,4,5-alkoxy and 2,3,4-alkoxy benzamide derivatives as pde-iv (phophodiesterase type-iv) inhibitors for the treatment of inflammatory diseases such as asthma
ATE533485T1 (de) † 2005-10-31 2011-12-15 Merck Sharp & Dohme Cetp-inhibitoren
EP1790345A1 (en) * 2005-11-02 2007-05-30 Esbatech AG Triazin beta-secretase inhibitors
US7671221B2 (en) * 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
CA2856037C (en) * 2005-12-28 2017-03-07 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
JP5764290B2 (ja) 2006-06-26 2015-08-19 マクロジェニクス，インコーポレーテッド ＦｃγＲＩＩＢ特異的抗体およびその使用法
WO2010045633A2 (en) * 2008-10-17 2010-04-22 National Jewish Health Measurement and analysis of leukotrienes
WO2010075376A2 (en) 2008-12-23 2010-07-01 Abbott Laboratories Anti-viral compounds
CA2740195A1 (en) 2008-12-23 2010-07-01 Abbott Laboratories Anti-viral compounds
EP2419404B1 (en) 2009-04-15 2015-11-04 AbbVie Inc. Anti-viral compounds
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
DK2455376T3 (en) 2009-06-11 2015-03-02 Abbvie Bahamas Ltd Heterocyclic compounds as inhibitors of hepatitis C virus (HCV)
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
US8420655B2 (en) 2009-12-04 2013-04-16 Boehringer Ingelheim International Gmbh Benzimidazole inhibitors of leukotriene production
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
PT2595965T (pt) * 2010-07-20 2016-08-22 Vestaron Corp Triazinas e pirimidinas inseticidas
JP5928958B2 (ja) 2010-10-29 2016-06-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン生成のベンゾイミダゾールインヒビター
JP5789888B2 (ja) 2010-11-01 2015-10-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン生成のベンゾイミダゾールインヒビター
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
WO2019018562A1 (en) 2017-07-19 2019-01-24 Ideaya Biosciences, Inc. AMIDO COMPOUND AS MODULATORS OF AHR
MX2021003093A (es) * 2018-09-18 2021-05-12 Terns Inc Compuestos para tratar ciertas leucemias.
CN110054558B (zh) * 2019-05-16 2022-03-25 海门瑞一医药科技有限公司 一种1-三氟甲基环丙烷-1-甲酸的制备方法
CN112441983B (zh) * 2019-08-29 2023-09-15 山东福长药业有限公司 一种基于苯并咪唑取代的硝基苯的化合物及其制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3017610A (en) * 1957-03-15 1962-01-16 Curtiss Wright Corp Electronic data file processor
US4939133A (en) 1985-10-01 1990-07-03 Warner-Lambert Company N-substituted-2-hydroxy-α-oxo-benzeneacetamides and pharmaceutical compositions having activity as modulators of the arachidonic acid cascade
LU86258A1 (fr) 1986-01-21 1987-09-03 Rech Dermatologiques C I R D S Composes benzamido aromatique,leur procede de preparation et leur utilisation en medecine humaine ou veterinaire et en cosmetique
US4744026A (en) * 1986-04-11 1988-05-10 American Telephone And Telegraph Company, At&T Bell Laboratories Methods and apparatus for efficient resource allocation
IT1232252B (it) * 1989-02-22 1992-01-28 Rotta Research Lab Derivati della n fenil benzamide ad attivita' antiulcera ed antiallerica e procedimento per la loro preparazione
EP0428939B1 (de) * 1989-11-21 1996-01-17 Bayer Ag Cumarinderivate, Verfahren zu ihrer Herstellung, ihre Verwendung und Thiazolyl-essigsäurederivate als Zwischenprodukte
ATE128030T1 (de) * 1990-08-02 1995-10-15 Hoffmann La Roche Antiallergische mischung.
IE71647B1 (en) * 1991-01-28 1997-02-26 Rhone Poulenc Rorer Ltd Benzamide derivatives
WO1993025517A1 (en) * 1992-06-15 1993-12-23 Celltech Limited Trisubstituted phenyl derivatives as selective phosphodiesterase iv inhibitors
US5521813A (en) * 1993-01-15 1996-05-28 Strategic Weather Services System and method for the advanced prediction of weather impact on managerial planning applications
US5496826A (en) * 1994-09-02 1996-03-05 Bristol-Myers Squibb Company Pharmaceutical methods of using heterocyclic derivatives of N-phenylamides
US5821258A (en) * 1994-12-27 1998-10-13 Mitsui Chemicals, Inc. Phenylbenzimidazole derivatives
AU4988997A (en) * 1996-10-23 1998-05-15 Osteoscreen, Inc. Compositions and methods for treating bone deficit conditions
US6988076B2 (en) * 1997-05-21 2006-01-17 Khimetrics, Inc. Strategic planning and optimization system
CZ20004350A3 (cs) * 1998-05-22 2002-02-13 Avanir Pharmaceuticals Benzimidazolové deriváty jako modulátory IgE
US6910017B1 (en) * 1999-03-05 2005-06-21 Profitlogic, Inc. Inventory and price decision support
US6405175B1 (en) * 1999-07-27 2002-06-11 David Way Ng Shopping scouts web site for rewarding customer referrals on product and price information with rewards scaled by the number of shoppers using the information
US6546387B1 (en) * 1999-11-15 2003-04-08 Transcom Software Inc. Computer network information management system and method using intelligent software agents
US20020042739A1 (en) * 2000-03-13 2002-04-11 Kannan Srinivasan Method and system for creating and administering internet marketing promotions
US20020023001A1 (en) * 2000-07-11 2002-02-21 Mcfarlin James A. Method and apparatus for online creation and sale of custom local store marketing materials
US7072848B2 (en) * 2000-11-15 2006-07-04 Manugistics, Inc. Promotion pricing system and method
US20020198794A1 (en) * 2001-06-21 2002-12-26 Williams Edward P. Inventory management system for determining suggested part stocking levels for a vehicle dealer

Also Published As

Publication number Publication date
MXPA00011470A (es) 2002-10-17
CN1311679A (zh) 2001-09-05
BR9910641A (pt) 2001-10-02
HUP0102128A3 (en) 2002-05-28
PL345219A1 (en) 2001-12-03
RU2236221C2 (ru) 2004-09-20
IL139828A0 (en) 2002-02-10
WO1999061020A1 (en) 1999-12-02
CN1721411A (zh) 2006-01-18
EP1077700B1 (en) 2005-04-06
CA2332985A1 (en) 1999-12-02
HUP0102550A3 (en) 2002-11-28
CN1219510C (zh) 2005-09-21
AU754943B2 (en) 2002-11-28
JP2002516276A (ja) 2002-06-04
CZ20004351A3 (cs) 2001-10-17
EP1077695A2 (en) 2001-02-28
US6451829B2 (en) 2002-09-17
BR9910642A (pt) 2001-10-09
AU4312099A (en) 1999-12-13
CN1317965A (zh) 2001-10-17
KR100591652B1 (ko) 2006-06-26
PL345952A1 (en) 2002-01-14
WO1999061013A2 (en) 1999-12-02
DE69924607T2 (de) 2006-02-02
AU754562B2 (en) 2002-11-21
NO20005889L (no) 2001-01-22
AU4197899A (en) 1999-12-13
WO1999061019A1 (en) 1999-12-02
CN1311675A (zh) 2001-09-05
JP2002516277A (ja) 2002-06-04
IL139827A0 (en) 2002-02-10
CA2332999A1 (en) 1999-12-02
NO20005887D0 (no) 2000-11-21
MXPA00011422A (es) 2002-12-13
CA2332989A1 (en) 1999-12-02
JP2002516274A (ja) 2002-06-04
CZ20004350A3 (cs) 2002-02-13
HUP0102128A2 (hu) 2002-03-28
BR9910640A (pt) 2001-10-30
NZ508416A (en) 2004-01-30
HUP0101894A3 (en) 2002-07-29
PL345560A1 (en) 2001-12-17
ES2241285T3 (es) 2005-10-16
US20020010343A1 (en) 2002-01-24
NO20005888D0 (no) 2000-11-21
NO20005887L (no) 2001-01-19
US6271390B1 (en) 2001-08-07
ZA200007754B (en) 2001-08-16
KR20010030179A (ko) 2001-04-16
HUP0101894A2 (hu) 2002-02-28
RU2236220C2 (ru) 2004-09-20
HUP0102550A2 (hu) 2001-10-28
UA67774C2 (uk) 2004-07-15
AU4094299A (en) 1999-12-13
EP1079830A1 (en) 2001-03-07
NO20005888L (no) 2001-01-22
WO1999061013A3 (en) 2000-04-06
DE69924607D1 (de) 2005-05-12
EP1077700A1 (en) 2001-02-28
ATE292465T1 (de) 2005-04-15
IL139826A0 (en) 2002-02-10
UA67775C2 (uk) 2004-07-15
MXPA00011467A (es) 2002-10-17
ZA200007753B (en) 2001-07-18
ZA200007752B (en) 2001-12-05
NZ508413A (en) 2003-08-29

Similar Documents

Publication Publication Date Title
NO20005889D0 (no) Benzimidazolanaloger som ned-regulatorer av IgE
BR0314235A (pt) Compostos de fenil-aza-benzimidazol para modulação de ige e inibição da proliferação celular
AR034023A1 (es) Compuestos benzimidazoles para modular la ige e inhibir la proliferacion celular
ATE433973T1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
BR0316350A (pt) Diaminotriazóis úteis como inibidores de proteìna cinases
HUP0400659A2 (hu) Kitinázokkal, kitinázszerű molekulákkal és gyulladásos megbetegedéssel kapcsolatos eljárások, készítmények és reagenskészletek
EE200200684A (et) Piperasiini derivaadid ja nende kasutamine põletikuvastaste vahenditena
CY1107531T1 (el) Χρηση αναστολεων πρωτεασομης για την αγωγη των διαταραχων ξηρου οφθαλμου
BRPI0409097A (pt) derivados de imidazol para tratamento de distúrbios alérgicos e hiperproliferativos
WO2004024896A3 (en) Phenyl-indole compounds
ATE417616T1 (de) Behandlung von mukositis
SE0302304D0 (sv) Novel compounds
DE602004009414D1 (de) BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN MIT N-2,3,3-TETRAMETHYLBICYCLOi2.2.1öHEPTAN-2-AMINE
DE60322376D1 (de) Sedative stoffe und behandlungen
NO20053247L (no) Anvendelse av levocetirizin ved behandling av vedvarende allergisk rhinitt.
ATE305041T1 (de) Kompositionen und verwendungen von cgi-69
SE9901273D0 (sv) Novel compounds
DE50214750D1 (de) Kinase inhibitoren und deren verwendung
SE0004892D0 (sv) Group 2 allergen specific IgE-Fabs and use thereof
PT1032415E (pt) Prevencao e/ou tratamento de condicoes alergicas
TH83887B (th) สารประกอบเฟนิล-อะซา-เบนซิมิดาโซล สำหรับใช้ปรับ IgE และยับยั้งการแพร่ขยายของเซลล์
UY26875A1 (es) Compuestos de 1,4-dihidropiridina como antagonistas de bradicinina